Chemours price target raised to $36 from $33 at RBC Capital

RBC Capital analyst Arun Viswanathan raised the firm’s price target on Chemours to $36 from $33 but keeps a Sector Perform rating on the shares after its Q4 earnings miss. The company’s results were impacted by lower fixed cost absorption in TiO2, which should improve through 2023 from a recovery in China and Europe, the analyst tells investors in a research note. The firm adds however that it also sees some macro uncertainties in TiO2 demand from coatings and electronics markets.